Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on Tenet Healthcare (NYSE:THC) with a price target of $177.00. The healthcare provider, currently trading near its 52-week high of $178.76 and commanding a market capitalization of $16.48 billion, has shown strong momentum with a P/E ratio of 11.69.
The firm cited an attractive setup for the healthcare provider based on several key metrics that align with its survey results. Inpatient admissions consensus on both volume and pricing trends are tracking in line with the firm’s survey findings. According to InvestingPro data, Tenet maintains a "GREAT" overall financial health score of 3.4, supporting the positive outlook.
Tenet’s outpatient volumes are currently at 1.3%, compared to survey results of 1.6%, with the firm noting that THC has the lowest consensus expectations among its peer group in this category.
The firm also highlighted that consensus estimates allow for a 150 basis point increase in SWB (salaries, wages, and benefits) in the second quarter of 2025 compared to the first quarter. This makes Tenet the only provider in its coverage universe whose labor trend quarter-over-quarter aligns with the firm’s survey results.
Cantor Fitzgerald’s maintained price target of $177.00 reflects its continued confidence in Tenet Healthcare’s positioning within the healthcare provider space.
In other recent news, Tenet Healthcare has been the focus of various analyst reports and shareholder activities. S&P Global Ratings upgraded Tenet Healthcare to ’BB-’ from ’B+’, highlighting the company’s improved credit profile and successful expansion of its ambulatory surgery business, which now accounts for 24% of its total revenue. Cantor Fitzgerald maintained its Overweight rating on Tenet, noting stability in physician openings and nursing employment trends. Meanwhile, BofA Securities increased its price target for Tenet to $180, citing confidence in the company’s strategic initiatives and growth in its Ambulatory Surgery Center (ASC) business. Goldman Sachs also adjusted its price target to $154 while maintaining a Neutral rating, reflecting Tenet’s strong fundamentals and effective cost management in its Hospital segment. At Tenet’s 2025 Annual Meeting of Shareholders, all nominated directors were elected with strong support, and executive compensation was approved. However, a proposal regarding maternal health outcomes did not pass. These developments underscore Tenet’s ongoing efforts to navigate industry challenges and capitalize on growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.